lcerative colitis is a relapsing disease of unknown cause characterized by bloody diarrhea. Therapy usually involves 5-aminosalicylates, which are of limited benefit, with a response rate between 30 and 80 percent, depending on the end point used, 1 or corticosteroids such as prednisolone, although resistance and dependency can become problematic with corticosteroids. 2 Immunosuppressive drugs, such as azathioprine, are beneficial but may have serious side effects. 3 New therapeutic approaches are therefore needed.
Recombinant peptides are increasingly being used for clinical purposes; for example, epoetin is used for anemia related to renal failure. Human epidermal growth factor (EGF) is a potent mitogenic peptide produced by salivary and duodenal Brunner's glands, 4 which stimulates several components of the healing response. 5 Preliminary studies in humans suggest that topical EGF enhances healing of skin wounds 6 and that systemic EGF is beneficial for necrotizing enterocolitis in neonates. 7 We therefore examined the value of luminal (enema) EGF therapy for patients with active left-sided ulcerative colitis or proctitis (ulceration limited to the rectum).
patients
Subjects were recruited from patients with active colitis who attended the emergency colitis clinic (thus including patients with acute relapse) and regular outpatient clinics at Leicester Royal Infirmary. Entry criteria were a worsening of symptoms requiring additional therapy and mild-to-moderate disease, as indicated by a score of at least 5 on the St. Marks index 8 (in which a score of 12 indicates the most severe disease) with a score of at least 1 (on a scale of 0 [normal] to 3 [most severe inflammation]) on sigmoidoscopy. 8 Patients were excluded if they required hospitalization or intravenous corticosteroid therapy or if they were taking topical or systemic corticosteroids, if their treatment had changed in the three months before the study began, or if inflammation extended proximally to the left side of the colon (i.e., beyond the splenic flexure on fiberoptic endoscopy). Patients who had had no changes in their immunosuppressive-therapy regimen in the three months before recruitment to the study were eligible.
study design
Patients were randomly assigned in a double-blind fashion to receive an EGF or placebo enema for 14 days. A permuted-block design was used to achieve equal numbers in each group. To ensure that all patients received an active treatment, all patients received a pH-dependent, slow-release oral preparation of mesalamine (Asacol, GlaxoSmithKline). Patients who were not taking mesalamine at recruitment began to take 1.2 g per day, whereas patients who were already taking mesalamine had their dose increased by 1.2 g per day. Patients were assessed clinically, sigmoidoscopically, and histologically at the start of the study, at two weeks, and at four weeks. At the two-week assessment, the enema medication was discontinued but mesalamine therapy was continued at the same dose. At the fourweek assessment, patients who were in remission reverted to their original pretrial regimen (no treatment or continued mesalamine), whereas those with active disease had their medication increased or changed according to clinical need; in most cases, additional corticosteroid therapy or mesalamine therapy or both were given. The four-week assessment marked the end of the trial period, although all patients underwent a final clinical review 12 weeks after entry. The study remained double-blinded until after the 12-week review.
The study was approved by the Leicestershire Research Ethics Committee. All patients gave written informed consent.
enemas
Patients received daily enemas containing EGF or carrier alone. Human recombinant EGF (Heber Biotec, a commercial subsidiary of the Center for Genetic Engineering and Biotechnology, Havana, Cuba), expressed in Saccharomyces cerevisiae, comprises 60 percent EGF 1-52 (the EGF protein, lacking one terminal amino acid) and 40 percent EGF 1-51 (the EGF protein, lacking two terminal amino acids) and has bioactivity equivalent to that of full-length EGF 1-53 . 9 The EGF enema consisted of 5 µg of EGF in 100 ml of a degraded and modified gelatin carrier solution (Haemaccel 3.5 percent, Beacon Pharmaceuticals). This dose of EGF was chosen because it is similar to the concentration required to induce the maximal restitution response in intestinal cell lines. 10 A two-week period of enema therapy was chosen to maximize the likelihood of patients' compliance and because most standard therapies cur-rently used, such as corticosteroid therapy, usually have a positive result within this period. Placebo enema consisted of modified gelatin carrier alone and was indistinguishable from the EGF enema. Preliminary studies involving the incorporation of [ 3 H]thymidine into rat intestinal epithelium cells 10 confirmed that the inert carrier did not influence cell proliferation when it was given alone and that the biologic activity of the EGF remained stable during passage through the syringe and catheter, as previously described (data not shown). 9 Patients were taught to administer the enema themselves in the supine position before going to bed, using a 10-French rectal catheter attached to a 100-ml syringe. The patients gave themselves an enema once a day for 14 days (they were instructed to retain the preparation as long as possible) and then lay on each side for 15 minutes to ensure maximal contact of the enema preparation with the mucosa.
clinical scoring and definition of remission
At each assessment, patients completed a symptom questionnaire and underwent a clinical examination to generate three indexes of disease activity. The St. Marks index 8 and the ulcerative colitis disease-activity index 11 provide an assessment of disease activity based on a combination of symptoms, signs, and sigmoidoscopic findings, with scores ranging from 0 to 12 and 0 to 22, respectively. In both cases, lower scores mean less disease activity. We also analyzed the data using a simplified symptom score, which does not require information from sigmoidoscopy; patients were given a clinical-severity score that was based on an aggregate assessment of stool consistency, visible blood in stool, and nocturnal defecation, with a score of 0 or 1 for each, for a maximal score of 3. 12 Remission was defined by a St. Marks score of 4 or less with no inflammation on sigmoidoscopy. We also present the data using the ulcerative colitis disease-activity index, for which we defined remission as a score of 0 or 1 (no blood in stool), and using the simplified symptom score, for which we defined remission as a score of 0. 12 A clinical response was defined as a decrease of more than three points in the score on either the St. Marks index or the ulcerative colitis disease-activity index.
blood tests
At each visit, 10 ml of venous blood was obtained for the determination of the hemoglobin level, whitecell count, platelet count, albumin level, and C-reactive protein level.
sigmoidoscopic and histologic scoring
During the initial visit, all patients underwent a limited colonoscopic examination as far as the splenic flexure, at approximately 50 cm, and always above the upper limit of macroscopic disease. The second and third examinations were limited to the distal 25 cm. The mucosal appearance was given a score of 0, 1, 2, or 3, with 0 representing normal, 13 and three mucosal-biopsy specimens were obtained from a point halfway along the inflamed section of colon at the initial examination and at the same level at subsequent examinations for histologic grading. The biopsy specimens were fixed in formalin, sectioned, stained with hematoxylin and eosin, and given a score of 0, 1, 2, or 3 8 ; a score of 0 represented normal histologic findings. Mucosal-biopsy specimens were assessed in a blinded fashion by a single investigator.
study end points
The primary end point of the study was disease remission (as defined by a St. Marks score of 4 or less) at two weeks. Secondary end points were clinically significant improvements in the clinical and histologic scores at two and four weeks.
statistical analysis
With 12 patients per group, the study had 80 percent power to detect a significant difference in proportions between a 10 percent rate of remission in the placebo group and a 60 percent rate of remission in the EGF group at a P value of 0.05 when the data were evaluated with use of a chi-square test. Data were analyzed in a blinded fashion according to the intention-to-treat principle. The Wilcoxon signedrank test for paired samples was used to compare differences within treatment groups, and the MannWhitney U test was used to compare differences between the groups. Fisher's exact test was used to compare remission rates in the two groups. A planned interim analysis was conducted after 15 patients had completed the trial. All reported P values are based on two-sided t-tests.
Five patients in the placebo group and four in the EGF group had proctitis. One patient in the EGF group was taking azathioprine at recruitment, and the dose had been unchanged for more than three months before recruitment. No patients were receiving long-term topical mesalamine therapy at the time of recruitment.
There were no significant differences between the groups in any of the recorded base-line symptoms, signs, or hematologic, biochemical, sigmoidoscopic, or histologic characteristics ( Table 1) . The median daily dose of mesalamine at both two and four weeks was 2.4 g (range, 1.2 to 2.8) in both groups. All 24 patients gave themselves the enema and retained the solution for more than 45 minutes per day for 14 days.
two-week assessment
At the end of the two weeks of enemas, all 12 patients in the EGF group had significant decreases in the St. Marks score (P=0.005) ( Table 2 ) and the score on the ulcerative colitis disease-activity index (P<0.001) (Fig. 1A) , as compared with 2 of 12 patients in the placebo group. Remission as defined by a St. Marks score of 4 or less was achieved in 10 of 12 patients in the EGF group, as compared with 1 of 12 in the placebo group (P<0.001). Remission as defined by a score on the ulcerative colitis diseaseactivity index of 0 or 1 was achieved in 4 of 12 patients in the EGF group, as compared with 0 patients in the placebo group (P=0.09). Remission as defined by a simplified symptom score of 0 was achieved in 10 of 12 patients in the EGF group, as compared with 1 of 12 in the placebo group (P< 0.001) (Fig. 1B) . In both groups, hematologic and biochemical measurements were normal at the initial visit and remained so (Table 3) . No side effects were reported by any of the patients who were taking EGF.
Since only 6 of the 24 patients were not taking mesalamine at the time of recruitment, formal statistical analysis of this subgroup was not possible. However, the median St. Marks score improved by 6 points in the EGF group (three of three patients were in remission) and by 4 points in the placebo group (one of three were in remission).
Nine patients had proctitis. This number was insufficient for formal subgroup analysis, although the median St. Marks score improved by 6.5 points in the EGF group (four of four patients were in remission) and by 1 point in the placebo group (one of five was in remission).
* EGF denotes epidermal growth factor, and UCDAI ulcerative colitis diseaseactivity index. † A score of 4 or less represented remission, with no inflammation on sigmoidoscopy. ‡ A score of 0 or 1 represented remission, with no visible blood in stool. § A score of 0 represented remission. The new england journal of medicine Two patients in the placebo group were withdrawn from the study at two weeks because of a worsening of symptoms (diarrhea with blood) and disease activity, although the investigators were unaware of the patients' treatment assignments. This represents failure of treatment, and these patients were included in the denominator for all chi-square tests. Since they were not assessed after their withdrawal from the study, their data were not included in calculations of the median values, ranges, and statistical analyses (Wilcoxon and Mann-Whitney tests) relating to disease activity. Significant improvements in clinical, sigmoidoscopic, and histologic measurements were found in the EGF group but not in the placebo group (Table 2) .
four-week assessment
At four weeks, disease-activity scores in the EGF group were significantly better than both pretreatment values and the four-week values in the placebo group (Table 2 and Fig. 1A ). When remission was defined according to the St. Marks score, 10 of 12 patients were in remission in the EGF group, as compared with 3 of 12 in the placebo group (P= 0.012). When remission was defined according to the score on the ulcerative colitis disease-activity index, 7 of 12 patients were in remission in the EGF group, as compared with 1 of 12 in the placebo group (P=0.03). When remission was defined according to the simplified symptom score, 10 of 12 patients in the EGF group were in remission, as compared with 3 of 12 in the placebo group (P= 0.01) (Fig. 1B) .
12-week assessment
Since patients did not undergo sigmoidoscopy at the 12-week assessment, we could not calculate the St. Marks score or the score on the ulcerative colitis disease-activity index. However, 8 of 12 patients (67 percent) who had been treated with EGF and who were in histologic remission at four weeks remained in remission defined according to the simplified symptom score, as compared with only 1 in the placebo group (8 percent 
subsequent review
We reviewed the patients' records retrospectively to determine the number who subsequently received corticosteroid treatment. The decision to use corticosteroids was made by the attending physician on the basis of his or her normal clinical criteria. By 6 months, 6 of the 12 EGF-treated patients had required local or systemic corticosteroids, and by the last review, at a median of 16 months, 8 of the 12 had required local or systemic corticosteroids. By six months, all the patients in the placebo group had required local or systemic corticosteroids.
We found that once-daily EGF enemas induced rapid improvements in active left-sided ulcerative colitis or proctitis when administered in combination with oral mesalamine. The condition of all patients who received EGF improved within two weeks, and 10 of 12 (83 percent) were in remission according to the discussion * Data were missing for two patients in the placebo group who were withdrawn from the study at two weeks because of worsening symptoms. † A score of 4 or less represented remission, with no inflammation on sigmoidoscopy. ‡ P<0.01 for the comparison with the value before treatment. § A score of 0 represented remission, with no visible blood in stool. ¶ No dysplasia was observed in any biopsy specimen at any time. St. Marks score. In contrast, only two patients who received placebo plus mesalamine had an improvement, and only one of the two was in remission. After 12 weeks there was no clinical evidence of early relapse in patients in whom remission was achieved with EGF therapy. Previous studies have reported response rates to placebo of 16 to 52 percent, 14 although the number of patients who have a spontaneous full remission is probably much lower.
Mesalamine is a well-established agent for colitis therapy that is superior to placebo, 15 has dosedependent efficacy, 16 and is useful when given both topically and orally for distal colonic disease. 17 The lack of a major response to mesalamine therapy in our study is probably related to the relatively small additional oral dose used (1.2 g per day). EGF is a 1207-amino-acid precursor 18 that is processed to a polypeptide of 53 amino acids (EGF 1-53 ). Circulating levels of EGF are low and consist mostly of the EGF 1-52 form, 19 which is bound to platelets and not readily available to the gastrointestinal mucosa. Although EGF enters the proximal gastrointestinal tract as EGF 1-53 , it is susceptible to progressive digestion as it proceeds distally. In acidic gastric juice, it is cleaved mainly to EGF 1-49 , reducing its activity by 75 percent. 20 Once EGF enters the small intestine, it is rapidly digested by pancreatic proteases within the lumen but may be partially protected against digestion by the presence of food. 21 Under physiologic conditions, it is therefore likely that very little luminal EGF derived from the upper intestine reaches the colon, and any orally administered EGF is unlikely to reach the distal bowel unless it is protected from digestion. Administration of EGF as an enema has the advantage of delivering the peptide to the injured area in a readily available, intact, active form. To ensure that adequate active EGF reached the inflamed mucosa, we administered an enema containing 100 times the concentration of EGF found in gastric juice (500 ng per liter), 20, 22 an amount sufficient to stimulate the proliferation of intestinal cells in vitro. 10, 19, 20 EGF probably acts through several mechanisms. It is a potent stimulant of cell migration (restitution) and cell proliferation, 10,20 both of which are important in reestablishing epithelial continuity. 5 EGF also reduces injury and stimulates repair in animal models of gastric, small intestinal, and colonic injury, 9, 20, [23] [24] [25] although the exact mechanisms of this effect remain unclear. In our patients, it is likely that EGF facilitated the reformation of the epithelial barrier, and this in turn reduced the secondary inflammatory response to luminal antigens. Most studies of the distribution of EGF receptors in the normal human bowel suggest that they are restricted to the basolateral membranes. 26 Our luminal therapy probably stimulated repair by means of EGF receptors exposed at the sites of injury, in keeping with the role of EGF as a luminal surveillance peptide. 5 Other potential mechanisms include an increase in the numbers of receptors 27 and an alteration in the distribution of receptors to include apical membranes. 28 The cause of ulcerative colitis is unclear but probably involves an imbalance between aggressive factors and mucosal defense and repair. Since EGF is important in repair mechanisms, a local or generalized defect in its production, its receptor, or the rate of its destruction may be etiologic factors. Reduced plasma levels of EGF are found in neonates with necrotizing enterocolitis, 7 and when the EGF receptor is deleted in mice, 29 bowel ulceration results.
The use of recombinant peptides for so-called hollow-organ gastrointestinal conditions is at a preliminary stage. 30 Many of the favorable outcomes reported with the use of recombinant peptides in animal models of gastrointestinal disease are seen only if the peptides are administered before exposure to the damaging agent, limiting their clinical relevance. Systemic therapy with potent growth factors, such as EGF, could theoretically stimulate premalignant lesions in distant organs. It is therefore prudent to limit systemic therapy to life-threatening conditions, as occurred in the case of a child with necrotizing enterocolitis 7 and in a child with congenital microvillous atrophy. 31 Luminal therapy overcomes many of these problems, since EGF will only influence the growth and repair of the damaged areas, where the basolateral receptors are exposed. Although we found no colonic dysplasia in this short-term study, serial biopsies of the affected area in patients given exogenous EGF seem appropriate until potential safety issues have been addressed.
In summary, our finding that EGF enemas reduced disease activity and induced clinical remission expands on previous studies in vitro and in animal models. To determine optimal doses and delivery methods, larger studies that directly compare EGF with high-dose mesalamine or corticosteroids appear to be warranted. Dr. Nightingale reports owning equity in GlaxoSmithKline. Dr. Playford reports having received lecture fees from Lonza and grant support from Scientific Hospital Supplies.
We are indebted to S. Ghosh, Imperial College, London, for statistical advice.
* Data were missing for two patients in the placebo group who were withdrawn from the study at two weeks because of worsening symptoms. There were no significant differences between or within the groups. 
